N-(pyridin-2-yl)-6,7,8,9-tetrahydro-5h-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds as GPR65 modulators for the treatment of cancer

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof,

• wherein:
• ring A is benzene, pyridine, pyridone, pyridine N-oxide, pyrimidone, pyridazine, pyrazine, or isoxazole ring that is optionally substituted with one or more substituents selected from halo, CN, alkoxy, NR11R11′, OH, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents each independently selected from halo, CN, alkoxy, NR11R11′, OH, alkyl, haloalkyl, and aralkyl;
• ring B is a monocyclic or bicyclic heteroaromatic group containing at least one nitrogen atom, which is optionally substituted by one or more substituents selected from halo, CN, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CO2-alkyl and O-aryl;
• Y is selected from CH2, C═N—OH, and CR10R10′, wherein R10 and R10′ are each independently selected from H, F, alkyl, and haloalkyl;
• Ra and Rb are each independently selected from H and alkyl;
• R11 and R11′ are each independently selected from H, alkyl, haloalkyl, COR12, CO2R13 and SO2R16, wherein R12, R13 and R16 are each independently alkyl.